Merck and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab

[Business Wire] – As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab*, an investigational immune checkpoint inhibitor, the companies have announced today that they have a collaboration agreement in place with Dako, an Agilent Technologies company, for the development of a potential companion diagnostic test . http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/merck-pfizer-collaborate-dako-agilent-210000738.html